Citi Global Healthcare: SMID-Cap Biotech at the Crossroads of Healthcare and AI
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Citi examines how artificial intelligence is reshaping strategy for small- and mid-cap (SMID-cap) biotechnology companies, arguing that AI is evolving from a productivity tool into a broader strategic enabler. In the near term, value comes mainly from workflow automation and improved data access; over the longer horizon, the core opportunity lies in accelerating drug discovery, refining candidate selection, and easing industry bottlenecks such as patient recruitment. The report stresses that successful AI adoption depends on access to high-quality data and rigorous validation of outputs. Scientific expertise, human judgment, and strong governance frameworks are described as essential complements to the technology, ensuring that results remain scientifically sound rather than merely fast. Citi frames the sequencing as follows: SMID-cap biotechs face R&D bottlenecks; AI upgrades from tool to strategic enabler; value realization moves from near-term automation and data access to longer-term gains in discovery, screening, and recruitment; and success rests on high-quality data combined with scientific judgment and governance. Citi expects AI adoption in biotech to keep advancing rapidly, but cautions that success will depend heavily on human expertise and governance. The report names no specific recommended stocks or target prices.